NASDAQ:TMCI Treace Medical Concepts (TMCI) Stock Forecast, Price & News $13.11 +0.91 (+7.46%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$12.61▼$13.3050-Day Range$12.16▼$23.2652-Week Range$11.85▼$27.97Volume762,381 shsAverage Volume624,710 shsMarket Capitalization$806.79 millionP/E RatioN/ADividend YieldN/APrice Target$27.30 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Treace Medical Concepts MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside108.2% Upside$27.30 Price TargetShort InterestHealthy3.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.72) to ($0.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector355th out of 970 stocksSurgical & Medical Instruments Industry46th out of 99 stocks 3.4 Analyst's Opinion Consensus RatingTreace Medical Concepts has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.30, Treace Medical Concepts has a forecasted upside of 108.2% from its current price of $13.11.Amount of Analyst CoverageTreace Medical Concepts has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.83% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Treace Medical Concepts has recently increased by 28.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMCI. Previous Next 2.6 News and Social Media Coverage News SentimentTreace Medical Concepts has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Treace Medical Concepts to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.Percentage Held by Insiders28.69% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.85% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.72) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -17.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -17.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 12.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Treace Medical Concepts (NASDAQ:TMCI) StockTreace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision; and Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.Read More TMCI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMCI Stock News HeadlinesSeptember 29, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Treace Medical ConceptsSeptember 20, 2023 | finance.yahoo.comTreace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023September 30, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 17, 2023 | fool.comTreace Medical Concepts (NASDAQ: TMCI)September 14, 2023 | finance.yahoo.comTreace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. PatentSeptember 11, 2023 | finance.yahoo.comTreace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related ProceduresAugust 22, 2023 | finance.yahoo.comTreace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare ConferenceAugust 21, 2023 | finance.yahoo.comTreace Medical Concepts Appoints Nathan Minnich as Senior Vice President, MarketingSeptember 30, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 11, 2023 | nasdaq.comStephens & Co. Maintains Treace Medical Concepts (TMCI) Equal-Weight RecommendationAugust 10, 2023 | nasdaq.comTruist Securities Maintains Treace Medical Concepts (TMCI) Buy RecommendationAugust 9, 2023 | seekingalpha.comTreace Medical Concepts Non-GAAP EPS of -$0.20, revenue of $42MAugust 9, 2023 | finance.yahoo.comTreace Medical Concepts Reports Second Quarter 2023 Financial ResultsJuly 24, 2023 | finance.yahoo.comTreace Announces Participation in the UBS Medtech, Tools and Genomics Summit 2023July 23, 2023 | markets.businessinsider.comTreace Medical Concepts (TMCI) Receives a Buy from Truist FinancialJuly 20, 2023 | msn.comTreace Medical: New Surgeons, Higher ASPs, And More Lapiplasties: A Positive TrendJuly 18, 2023 | finance.yahoo.comTreace to Report Second Quarter 2023 Financial Results on August 8, 2023July 12, 2023 | finance.yahoo.comTreace Appoints Julie Dewey as Chief Communications and Investor Relations OfficerJuly 10, 2023 | finance.yahoo.comWhile Treace Medical Concepts (NASDAQ:TMCI) shareholders have made 43% in 1 year, increasing losses might now be front of mind as stock sheds 5.0% this weekJuly 8, 2023 | finance.yahoo.comTMCI - Treace Medical Concepts, Inc.June 13, 2023 | finance.yahoo.comTreace Medical Completes Acquisition of Technology Enabling Patient Specific Instrumentation and Reports on Clinical Cases Using PSI with the Lapiplasty® SystemJune 5, 2023 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) is largely controlled by institutional shareholders who own 58% of the companyJune 2, 2023 | msn.comStephens & Co. Reiterates Treace Medical Concepts (TMCI) Equal-Weight RecommendationJune 2, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Treace Medical Concepts (TMCI)June 2, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Treace Medical ConceptsJune 1, 2023 | benzinga.comTreace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle SurgeriesJune 1, 2023 | msn.comTreace Medical Concepts buys certain assets of RedPoint Medical3DSee More Headlines Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address TMCI Company Calendar Last Earnings8/08/2023Today9/30/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TMCI CUSIPN/A CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees423Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.30 High Stock Price Forecast$30.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+108.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,810,000.00 Net Margins-25.32% Pretax Margin-25.32% Return on Equity-39.29% Return on Assets-20.76% Debt Debt-to-Equity Ratio0.35 Current Ratio6.60 Quick Ratio5.73 Sales & Book Value Annual Sales$141.84 million Price / Sales5.69 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book12.03Miscellaneous Outstanding Shares61,540,000Free Float43,888,000Market Cap$806.79 million OptionableNot Optionable Beta0.01 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. John T. Treace (Age 51)CEO, Founder & Director Comp: $1.04MMr. Mark L. Hair CPA (Age 53)Chief Financial Officer Comp: $628.6kMr. Aaron J. Berutti (Age 44)Sr. VP of Sales Comp: $519.41kMr. Terry W. Lubben (Age 58)Sr. VP of Operations Ms. Julie D. Dewey (Age 62)Chief Communications & Investor Relations Officer Mr. Scot M. Elder (Age 48)Chief Legal & Compliance Officer and Corp. Sec. Mr. Nathan MinnichSr. VP of MarketingMr. Daniel E. Owens (Age 51)Chief HR Officer Mr. Jaime A. Frias (Age 61)Chief Bus. Devel. Officer Dr. Sean F. Scanlan Ph.D. (Age 40)Chief Innovation Officer More ExecutivesKey CompetitorsOrthoPediatricsNASDAQ:KIDSBeauty HealthNASDAQ:SKINSI-BONENASDAQ:SIBNAtrionNASDAQ:ATRINevroNYSE:NVROView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 225,000 shares on 8/24/2023Ownership: 3.603%California State Teachers Retirement SystemBought 21,784 shares on 8/21/2023Ownership: 0.081%VisionPoint Advisory Group LLCBought 5,347 shares on 8/21/2023Ownership: 0.009%Legato Capital Management LLCBought 19,270 shares on 8/18/2023Ownership: 0.031%Castleark Management LLCSold 5,470 shares on 8/16/2023Ownership: 0.201%View All Insider TransactionsView All Institutional Transactions TMCI Stock - Frequently Asked Questions Should I buy or sell Treace Medical Concepts stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMCI shares. View TMCI analyst ratings or view top-rated stocks. What is Treace Medical Concepts' stock price forecast for 2023? 5 Wall Street research analysts have issued 12-month price objectives for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $24.00 to $30.00. On average, they anticipate the company's stock price to reach $27.30 in the next year. This suggests a possible upside of 108.2% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts. How have TMCI shares performed in 2023? Treace Medical Concepts' stock was trading at $22.99 on January 1st, 2023. Since then, TMCI shares have decreased by 43.0% and is now trading at $13.11. View the best growth stocks for 2023 here. Are investors shorting Treace Medical Concepts? Treace Medical Concepts saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,660,000 shares, an increase of 28.7% from the August 31st total of 1,290,000 shares. Based on an average daily volume of 468,100 shares, the days-to-cover ratio is currently 3.5 days. Approximately 3.8% of the company's shares are short sold. View Treace Medical Concepts' Short Interest. When is Treace Medical Concepts' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our TMCI earnings forecast. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its earnings results on Tuesday, August, 8th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The business earned $41.95 million during the quarter, compared to the consensus estimate of $40.84 million. Treace Medical Concepts had a negative net margin of 25.32% and a negative trailing twelve-month return on equity of 39.29%. The company's revenue for the quarter was up 40.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.23) EPS. What guidance has Treace Medical Concepts issued on next quarter's earnings? Treace Medical Concepts updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $191.00 million-$197.00 million, compared to the consensus revenue estimate of $194.06 million. When did Treace Medical Concepts IPO? (TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. What is Treace Medical Concepts' stock symbol? Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI." How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Treace Medical Concepts' stock price today? One share of TMCI stock can currently be purchased for approximately $13.11. How much money does Treace Medical Concepts make? Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $806.79 million and generates $141.84 million in revenue each year. The company earns $-42,810,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. How many employees does Treace Medical Concepts have? The company employs 423 workers across the globe. How can I contact Treace Medical Concepts? Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net. This page (NASDAQ:TMCI) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.